DE602005015862D1 - Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien - Google Patents
Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologienInfo
- Publication number
- DE602005015862D1 DE602005015862D1 DE602005015862T DE602005015862T DE602005015862D1 DE 602005015862 D1 DE602005015862 D1 DE 602005015862D1 DE 602005015862 T DE602005015862 T DE 602005015862T DE 602005015862 T DE602005015862 T DE 602005015862T DE 602005015862 D1 DE602005015862 D1 DE 602005015862D1
- Authority
- DE
- Germany
- Prior art keywords
- prevention
- treatment
- kinase inhibitors
- associated pathologies
- hmgb1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59188004P | 2004-07-29 | 2004-07-29 | |
US64700705P | 2005-01-27 | 2005-01-27 | |
PCT/EP2005/008258 WO2006010628A1 (en) | 2004-07-29 | 2005-07-29 | Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005015862D1 true DE602005015862D1 (de) | 2009-09-17 |
Family
ID=35262096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005015862T Expired - Fee Related DE602005015862D1 (de) | 2004-07-29 | 2005-07-29 | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien |
Country Status (14)
Country | Link |
---|---|
US (1) | US20090191253A2 (de) |
EP (1) | EP1771178B1 (de) |
JP (1) | JP2008508220A (de) |
AT (1) | ATE438404T1 (de) |
AU (1) | AU2005266447A1 (de) |
CA (1) | CA2575272A1 (de) |
DE (1) | DE602005015862D1 (de) |
DK (1) | DK1771178T3 (de) |
ES (1) | ES2327659T3 (de) |
MX (1) | MX2007001155A (de) |
PL (1) | PL1771178T3 (de) |
PT (1) | PT1771178E (de) |
SI (1) | SI1771178T1 (de) |
WO (1) | WO2006010628A1 (de) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006298858A (ja) * | 2005-04-22 | 2006-11-02 | Yamaguchi Univ | 細胞内寄生性微生物に対し新規抑制効果を有するアポトーシス誘導剤 |
DK1919979T4 (en) | 2005-08-25 | 2017-07-17 | Creabilis Therapeutics Spa | Polymer conjugates of K-252A and derivatives thereof |
NZ565748A (en) * | 2005-09-07 | 2011-04-29 | Serono Lab | PI3K inhibitors for the treatment of endometriosis |
EP2284255B1 (de) | 2008-04-30 | 2017-10-18 | Genomix Co., Ltd. | Verfahren zum sammeln funktioneller zellen in vivo mit hoher effizienz |
WO2009133939A1 (ja) | 2008-04-30 | 2009-11-05 | 株式会社ジェノミックス | 末梢循環への骨髄由来多能性幹細胞動員薬 |
EP2334300B1 (de) | 2008-09-24 | 2016-02-17 | The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin | Zusammensetzung und verfahren zur behandlung von vorzeitigen wehen |
US20120165244A1 (en) * | 2008-10-30 | 2012-06-28 | Hua-Lin Wu | Methods for binding lewis y antigen |
JO3101B1 (ar) | 2008-12-02 | 2017-09-20 | Takeda Pharmaceuticals Co | مشتقات بنزوثيازول كعوامل مضادة للسرطان |
WO2010121175A1 (en) * | 2009-04-17 | 2010-10-21 | Rush University Medical Center | Combination targeted therapy for lung cancer |
BRPI1014405A2 (pt) | 2009-04-29 | 2016-04-05 | Amarin Corp Plc | composições farmacêuticas compreendendo epa e um agente cardiovascular e métodos de seu uso |
JP5467313B2 (ja) * | 2009-09-28 | 2014-04-09 | 国立大学法人 岡山大学 | アテローム動脈硬化抑制剤 |
CN104825491A (zh) | 2009-10-28 | 2015-08-12 | 吉诺米克斯股份有限公司 | 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂 |
ES2413437T3 (es) * | 2010-03-10 | 2013-07-16 | Institut Pasteur | HMGB1 y anticuerpos anti-HMGB1 en pacientes infectados por VIH especialmente con trastornos neurológicos |
ES2788394T3 (es) | 2011-04-26 | 2020-10-21 | Stemrim Inc | Péptido para inducir regeneración de tejido y uso del mismo |
FI20115640A0 (fi) | 2011-06-22 | 2011-06-22 | Turun Yliopisto | Yhdistelmähoito |
WO2013082458A1 (en) | 2011-12-02 | 2013-06-06 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
WO2014009609A1 (en) | 2012-07-13 | 2014-01-16 | Turun Yliopisto | Combination therapy iii |
EP2913058B1 (de) | 2012-10-25 | 2017-12-20 | Genomix Co., Ltd. | Neuartiges verfahren zur behandlung von herzinfarkt mit einem hmgb1-fragment |
KR102146822B1 (ko) | 2012-10-25 | 2020-08-21 | 가부시키가이샤 스템림 | Hmgb1 단편을 이용한 척수 손상에 대한 신규 치료법 |
JP2014162751A (ja) * | 2013-02-25 | 2014-09-08 | Dic Corp | 化合物、液晶組成物、及び表示装置 |
JP2014162752A (ja) * | 2013-02-25 | 2014-09-08 | Dic Corp | 化合物、液晶組成物、及び表示装置 |
JP6584494B2 (ja) * | 2014-09-12 | 2019-10-02 | ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company | メラニン産生細胞のhmgb1活性化を阻害する方法、そのような阻害に好適な薬剤を特定する方法 |
EP3522881A4 (de) * | 2016-10-05 | 2020-05-27 | Afecta Pharmaceuticals, Inc. | Hochmobile gruppe-b1-protein-inhibitoren |
BR112019014921A2 (pt) | 2017-01-27 | 2020-03-31 | StemRIM Inc. | Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica |
TWI645083B (zh) * | 2017-08-30 | 2018-12-21 | 金立德 | 篩選抑制發炎反應及血管保護活性物質之方法 |
JPWO2019107530A1 (ja) | 2017-12-01 | 2020-11-26 | 株式会社ステムリム | 炎症性腸疾患の治療薬 |
US11684653B2 (en) * | 2019-03-06 | 2023-06-27 | The Cleveland Clinic Foundation | Compositions and method for reducing virulence of microorganisms |
CN112574221B (zh) * | 2019-09-30 | 2022-03-04 | 上海纽思克生物科技有限公司 | 四环嘧啶酮类化合物、其制备方法、其组合物和用途 |
CN112176066B (zh) * | 2020-10-30 | 2022-07-01 | 中国科学院合肥物质科学研究院 | 一种宫颈病变早期筛查和诊断的分子标志物及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6041489A (ja) * | 1983-08-12 | 1985-03-05 | Kyowa Hakko Kogyo Co Ltd | 新規生理活性物質k―252 |
JPS62155284A (ja) * | 1985-12-27 | 1987-07-10 | Kyowa Hakko Kogyo Co Ltd | 生理活性物質k−252の誘導体 |
JPH0699311B2 (ja) * | 1986-11-06 | 1994-12-07 | 旭化成工業株式会社 | 抗血管レン縮剤および血管弛緩剤 |
JPH0826037B2 (ja) * | 1987-01-22 | 1996-03-13 | 協和醗酵工業株式会社 | 生理活性物質k−252の誘導体 |
US5633235A (en) * | 1991-04-19 | 1997-05-27 | Regents Of The University Of Michigan | Triciribine and analogs as antiviral drugs |
EP0541486A1 (de) * | 1991-11-07 | 1993-05-12 | Ciba-Geigy Ag | Polycyclische Konjugate |
US5756494A (en) * | 1992-07-24 | 1998-05-26 | Cephalon, Inc. | Protein kinase inhibitors for treatment of neurological disorders |
US6663881B2 (en) * | 1993-01-28 | 2003-12-16 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5441947A (en) * | 1993-08-25 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting vascular restenosis |
US5468872A (en) * | 1993-09-16 | 1995-11-21 | Cephalon, Inc. | K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders |
JPH07223958A (ja) * | 1994-02-14 | 1995-08-22 | Asahi Chem Ind Co Ltd | 血管肥厚抑制剤 |
US5705511A (en) * | 1994-10-14 | 1998-01-06 | Cephalon, Inc. | Fused pyrrolocarbazoles |
EP0711557A1 (de) * | 1994-11-09 | 1996-05-15 | Ciba-Geigy Ag | Pharmazeutische Formulierungsgrundlage |
EP0733372A3 (de) * | 1995-03-21 | 1998-05-20 | Ciba-Geigy Ag | Pharmazeutische Formulierungsgrundlage für Nanosuspensionen |
US5977184A (en) * | 1995-09-15 | 1999-11-02 | Thorne Research, Inc. | Quercetin chalcone and methods related thereto |
UA67725C2 (en) * | 1996-06-03 | 2004-07-15 | Cephalon Inc | K-252a derivatives and a method for improvement of functioning and cell survival enhancement |
ES2184106T3 (es) * | 1996-06-25 | 2003-04-01 | Cephalon Inc | Utilizacion del derivado de k-252a en el tratamiento de trastornos del sistema nervioso periferico o central, y de la hiperproduccion de citoquinas. |
NZ338108A (en) * | 1997-03-03 | 2004-12-24 | Univ Texas | Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections using roscovitine and olomoucine |
US6025365A (en) * | 1997-03-25 | 2000-02-15 | Arch Development Corp. | Chelerythrine and radiation combined tumor therapy |
US5998386A (en) * | 1997-09-19 | 1999-12-07 | Feldman; Arthur M. | Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue |
BR9910810A (pt) * | 1998-05-29 | 2001-02-13 | Gerhard Eisenbrand | Utilização de derivados de bisindóis indigóides |
US6231889B1 (en) * | 1998-09-21 | 2001-05-15 | Chronorx, Llc | Unit dosage forms for the treatment of herpes simplex |
MXPA01003761A (es) * | 1998-10-13 | 2003-07-21 | Kyowa Hakko Kogyo Kk | Agente para tratar oftalmopatia. |
CN1172673C (zh) * | 1998-11-23 | 2004-10-27 | 诺瓦提斯公司 | 星形孢菌素衍生物在制备治疗眼睛新血管生成性疾病的药物中的应用 |
DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
EP1218347A1 (de) * | 1999-08-19 | 2002-07-03 | Signal Pharmaceuticals, Inc. | Pyrazoloanthrone und deren derivate als jnk inhibitoren und ihre zusammensetzungen |
US20040072888A1 (en) * | 1999-08-19 | 2004-04-15 | Bennett Brydon L. | Methods for treating inflammatory conditions or inhibiting JNK |
US20010025059A1 (en) * | 2000-01-10 | 2001-09-27 | Kastke Floyd A. | Composition and method for treating non-bacterial prostatitis |
US7419678B2 (en) * | 2000-05-12 | 2008-09-02 | Cordis Corporation | Coated medical devices for the prevention and treatment of vascular disease |
JP2004517631A (ja) * | 2001-01-17 | 2004-06-17 | ヨウン メー パク | クエルセチンにより血管内皮成長因子及びエリスロポエチンの遺伝子発現を阻害する方法 |
ITMI20010562A1 (it) * | 2001-03-16 | 2002-09-16 | Marco E Bianchi | Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari |
US6649637B2 (en) * | 2001-03-16 | 2003-11-18 | Tyler Curiel | Inhibition of intracellular replication by pyridinylimidazoles |
US6703414B2 (en) * | 2001-09-14 | 2004-03-09 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Device and method for treating restenosis |
JP2006519623A (ja) * | 2001-10-25 | 2006-08-31 | ウィスコンシン・アルムナイ・リサーチ・ファウンデーション | タンパクチロシンキナーゼインヒビターで被覆されたまたは含浸された血管ステントまたは血管グラフト、およびその使用方法 |
EP1509614A4 (de) * | 2002-02-15 | 2007-09-12 | Gen Hospital Corp | Map-kinase inhibitoren zur regulierung von tumorassoziierten antigene expression |
US20040034084A1 (en) * | 2002-05-24 | 2004-02-19 | Celgene Corporation | Methods for using JNK inhibitors for treating or preventing disease-related wasting |
JP2005531607A (ja) * | 2002-06-05 | 2005-10-20 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | キナーゼ阻害剤として置換ピロリン |
WO2004032709A2 (en) * | 2002-10-04 | 2004-04-22 | Caritas St.Elisabeth's Medical Center Of Boston, Inc. | Inhibition of src for treatment of reperfusion injury related to revascularization |
EP1413887A1 (de) * | 2002-10-22 | 2004-04-28 | Aventis Pharma S.A. | Src Kinase Inhibitoren zur Behandlung von Alzheimer Krankheit |
GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
US20050019366A1 (en) * | 2002-12-31 | 2005-01-27 | Zeldis Jerome B. | Drug-coated stents and methods of use therefor |
TWI324604B (en) * | 2003-06-18 | 2010-05-11 | Novartis Ag | New use of staurosporine derivatives |
EP1653972A1 (de) * | 2003-07-23 | 2006-05-10 | Creabilis Therapeutics s.r.l. | Topische anwendung von tyrosinkinase-hemmern mikrobiellen ursprungs zur prävention und behandlung von hauterkrankungen, die durch übermässige zellproliferation gekennzeichnet sind |
WO2005074921A1 (en) * | 2004-02-09 | 2005-08-18 | University Of Zurich | Treatment of atherosclerosis |
-
2005
- 2005-03-11 MX MX2007001155A patent/MX2007001155A/es active IP Right Grant
- 2005-07-29 CA CA002575272A patent/CA2575272A1/en not_active Abandoned
- 2005-07-29 WO PCT/EP2005/008258 patent/WO2006010628A1/en active Application Filing
- 2005-07-29 AU AU2005266447A patent/AU2005266447A1/en not_active Abandoned
- 2005-07-29 US US11/658,701 patent/US20090191253A2/en not_active Abandoned
- 2005-07-29 JP JP2007523023A patent/JP2008508220A/ja active Pending
- 2005-07-29 EP EP05778429A patent/EP1771178B1/de not_active Not-in-force
- 2005-07-29 DK DK05778429T patent/DK1771178T3/da active
- 2005-07-29 ES ES05778429T patent/ES2327659T3/es active Active
- 2005-07-29 PL PL05778429T patent/PL1771178T3/pl unknown
- 2005-07-29 DE DE602005015862T patent/DE602005015862D1/de not_active Expired - Fee Related
- 2005-07-29 PT PT05778429T patent/PT1771178E/pt unknown
- 2005-07-29 AT AT05778429T patent/ATE438404T1/de not_active IP Right Cessation
- 2005-07-29 SI SI200530824T patent/SI1771178T1/sl unknown
Also Published As
Publication number | Publication date |
---|---|
PT1771178E (pt) | 2009-11-12 |
EP1771178A1 (de) | 2007-04-11 |
PL1771178T3 (pl) | 2010-01-29 |
ES2327659T3 (es) | 2009-11-02 |
DK1771178T3 (da) | 2009-11-02 |
US20090191253A2 (en) | 2009-07-30 |
WO2006010628A1 (en) | 2006-02-02 |
AU2005266447A1 (en) | 2006-02-02 |
EP1771178B1 (de) | 2009-08-05 |
MX2007001155A (es) | 2007-08-14 |
US20080317809A1 (en) | 2008-12-25 |
JP2008508220A (ja) | 2008-03-21 |
SI1771178T1 (sl) | 2010-01-29 |
ATE438404T1 (de) | 2009-08-15 |
CA2575272A1 (en) | 2006-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005015862D1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
EA200900779A1 (ru) | Производные дигидропиридина, полезные как ингибиторы протеинкиназы | |
EA200970447A1 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
TW200740815A (en) | P38 MAP kinase inhibitors and methods for using the same | |
EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
EA200601686A1 (ru) | Замещенные производные морфолина и тиоморфолина | |
EA201391705A1 (ru) | Триазолпиридиновые ингибиторы 11-бета-гидроксистероиддегидрогеназы типа i | |
TW200626068A (en) | Active compounds for seed treatment | |
DE602005009748D1 (de) | 3-phenyl-pyrazol-derivate als modulatoren des zur behandlung damit zusammenhängender störungen nützlichen 5-ht-2a-serotonin-rezeptors | |
EA200901483A1 (ru) | ПРОИЗВОДНЫЕ ПИРИМИДИНА И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
TW200634012A (en) | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
TW200736233A (en) | Cyclohexyl piperazinyl methanone derivatives | |
MX2007004248A (es) | Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa. | |
ATE446753T1 (de) | Verwendung von substituierten 2-thio-3,5-dicyano- 4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen | |
NO20082096L (no) | Azaindol-2-karboksamidderivativer | |
EA200801199A1 (ru) | Ингибиторы киназы | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
EA201100874A1 (ru) | Соединения для лечения рака | |
DE602006008583D1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
EA201100872A1 (ru) | Производные хиназолинамида | |
DE602007006328D1 (de) | 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren | |
TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |